A Nomogram Based on Serum Biomarkers and Clinical Characteristics to Predict Survival in Patients With Non-Metastatic Nasopharyngeal Carcinoma

Qing-Jie Li†, Yan-Ping Mao†, Rui Guo†, Cheng-Long Huang, Xue-Liang Fang, Jun Ma, Ling-Long Tang* and Lei Chen*

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

Objective: This study focused on developing an effective nomogram for improving prognostication for patients with primary nasopharyngeal carcinoma (NPC) restaged according to the eighth edition of the AJCC/UICC TNM staging system.

Methods: Based on data of 5,903 patients with non-metastatic NPC (primary cohort), we used Cox regression analysis to identify survival risk factors and created a nomogram. We used the nomogram to predict overall survival (OS), distant metastasis-free survival (DMFS) and disease-free survival (DFS) in the primary and independent validation (3,437 patients) cohorts. Moreover, we compared the prognostic accuracy between the 8th TNM system and the nomogram.

Results: The nomogram included gender, age, T stage, N stage, Epstein–Barr virus DNA, hemoglobin, C-reactive protein, lactate dehydrogenase, and radiotherapy with/without induction or concurrent chemotherapy. In the prediction of OS, DMFS and DFS, the nomogram had significantly higher concordance index (C-index) and area under ROC curve (AUC) than the TNM system alone. Calibration curves demonstrated satisfactory agreements between nomogram-predicted and observed survival. The stratification in different groups permitted remarkable differentiation among Kaplan–Meier curves for OS, DMFS, and DFS.

Conclusion: The nomogram led to a more precise prognostic prediction for NPC patients in comparison with the 8th TNM system. Therefore, it could facilitate individualized and personalized patients’ counseling and care.

Keywords: nasopharyngeal carcinoma, nomogram, serum biomarkers, prognostic prediction, survival
INTRODUCTION

Nasopharyngeal carcinoma (NPC), which arises from the nasopharynx epithelium, is the commonest head and neck malignant tumor in southeastern Asia and southern China (1). The risk factors for NPC contain genetic sensitivity, diet, Epstein–Barr virus infection and so on (2, 3). NPC caused 129,079 incident cases as well as triggered 72,987 deaths worldwide in 2018 (4). As for its treatment, radiotherapy is the mainstay therapy for patients with NPC. Additionally, combined chemoradiation has better efficaciousness in the therapy in advanced stage of NPC (5). Nevertheless, the survival of most NPC patients remains poor. Furthermore, though patients who were in the same TNM stage and obtained similar treatments, more than 20% of the patients showed poor effect (6), which indicated that therapy failure was partly attributed to the prognostic evaluation of the TNM staging system.

Therefore, besides trying our best to improve therapies for NPC, making prognostic evaluation more precise is also necessary for us to determine the malignant grade of NPC, and optimize treatment. The AJCC/UICC TNM staging system is the commonest prognostic factor. However, previous studies illustrated that sometimes this staging system fails to predict prognosis satisfactorily (7–9). Thus, recognizing factors related to prognosis can ameliorate the TNM staging system to predict survival of NPC patients. In recent years, an increasing number of serum markers, which can be conveniently gained, were regarded as prognostic markers for NPC patients, containing Epstein–Barr virus DNA (EBV-DNA) (10), hemoglobin (HGB) (11), albumin (ALB) (12), C-reactive protein (CRP) (13), lactate dehydrogenase (LDH) (14) and so on. These factors serve as practical biomarkers in common clinical testing.

Recently, nomograms function as new reliable tools for prognosis prediction in carcinomas (15–17). Nomograms involve some variables by analyzing their respective effects on survival and serve as convenient models to predict survival (18). Therefore, based on the data of 9,340 patients with non-metastatic NPC, we analyzed the prognostic effects of the serum factors on NPC. Besides hematological features, we also incorporated the TNM staging system and clinical factors to establish a nomogram to precisely predict overall survival (OS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) of NPC patients, which can aid clinical decision making and enhance treatment effects.

MATERIALS AND METHODS

Patients

NPC patients were divided into a primary cohort (5,903 patients, about 60% of all data in this study) and a validation cohort (3,437 patients, remaining about 40% of the data) according to the chronological order in which these patients received initial treatments. From January 2009 to June 2014, 5,903 primary NPC patients at Sun Yat-sen University Cancer Center were collected in the primary cohort. The inclusion criteria were as follows: [1] non-metastatic NPC patients confirmed by histopathology; [2] adequate clinical data and examination information; [3] no distant metastasis before or during therapies; [4] no evidence for other sources of tumor or other serious diseases. Additionally, we used the same criteria to screen 3,437 primary NPC patients from July 2014 to April 2016 at the same institution and regarded them as an independent validation cohort.

All NPC patients would receive radiotherapy with/without induction or concurrent chemotherapy. For NPC patients receiving induction chemotherapy (IC), docetaxel plus cisplatin/ nedaplatin plus 5-fluorouracil, or docetaxel plus cisplatin/nedaplatin, or gemcitabine plus cisplatin/nedaplatin, or cisplatin/nedaplatin plus 5-fluorouracil was administered every 3 weeks for three cycles before radiotherapy. Concurrent chemotherapy (CC) consisted of cisplatin administered every 3 weeks for 2–3 cycles (100 mg/m²) or weekly until the completion of radiotherapy (40 mg/m²). For NPC patients with a contraindication to cisplatin, nedaplatin or carboplatin was substituted.

The patients’ gender, age, smoking, or drinking history, family history of tumor, radiotherapy with/without induction chemotherapy (IC) or concurrent chemotherapy (CC), and serological data including pretreatment (pre-) EBV-DNA levels, pre-HGB, pre-ALB, pre-CRP, and pre-LDH, were obtained from the clinical records. We restaged all patients by the eighth edition of the AJCC/UICC TNM staging system. The data of all NPC patients’ serum biomarkers and clinical characteristics were measured and collected within the two weeks before initiating treatment. The Hospital Ethics Committee at Sun Yat-sen University Cancer Center in China approved the study, which analyzed anonymous information as well as waived the demand for informed consent.

Follow-Up

Our main endpoint was overall survival (OS), and secondary endpoints were distant metastasis-free survival (DMFS) as well as disease-free survival (DFS). Patients were followed up every three months in the first two years, every six months in the next three years, and annually thereafter until death.

Statistical Analysis

We transformed continuous variables into categorical variables. The age was grouped into <40, 40–49, 50–59, and ≥60 years old. According to the standard of anemia, pre-HGB was grouped into <120 g/L and ≥120 g/L. The optimal cut-off values for other continuous variables were determined by maximizing Youden’s index calculated in the data of the primary cohort, which serve as the difference between sensitivity and 1-specificity in the receiver operating characteristic (ROC) curves. Based on the maximizing Youden’s index of OS in NPC patients, all cut-off values were as follows: pre-EBV-DNA levels (4,000 copies/ml), pre-ALB (45 g/L), pre-CRP (2 mg/L), and pre-LDH (180 U/L).
Variables satisfying \( P < 0.05 \) in univariate Cox regression analyses were put into multivariable analysis. \( P < 0.05 \) in multivariable Cox regression analyses selected independent prognostic variables of survival. The TNM staging system and therapy items were regarded as necessary prognostic variables of survival in this study. All independent or necessary prognostic factors were used to create a predictive nomogram (by the package of rms in R).

The Akaike information criterion (AIC) and concordance index (C-index) with 95% confidence intervals (CIs) for the model were calculated to assess the accuracy of the nomogram in the primary and validation cohorts. Calibration plots for OS, DMFS, and DFS at three and five years were done by comparing predicted OS, DMFS, and DFS with actual OS, DMFS, and DFS. Moreover, for comparing the nomogram with the TNM staging system, the predictive precision and discrimination of the nomogram and the TNM system were analyzed by AIC, C-index (95% CI), area under curve (AUC) of ROC curves, and decision curves.

The curves for OS, DMFS, and DFS were performed using the Kaplan–Meier method. The comparisons of survival among three risk groups were analyzed using the log-rank test.

We completed the statistical analysis by R version 3.6.1 software (http://www.r-project.org) and IBM SPSS software version 25.0 (IBM, Armonk, NY, USA). Statistical data were all two-sided, and the significant effect was determined as \( P < 0.05 \).

RESULTS

Patient Characteristics and Follow-Up

5,903 (primary cohort) and 3,437 (validation cohort) patients with NPC were found eligible for this study. The median age was 45 (range, 7–80) years old for the primary cohort and 45 (range, 6–85) years old for the independent validation cohort. The male-to-female ratio was 2.86:1 (primary cohort) and 2.57:1 (validation cohort). Table 1 listed the comparisons between the primary cohort and validation cohort, for which patients in the validation cohort had poor N stage together with lower levels of pre-EBV-DNA, pre-HGB, pre-CRP, and pre-LDH.

The median follow-up for OS, DMFS, and DFS as well as the 3- and 5-year OS, DMFS, and DFS were shown in Table 2.

Univariate and Multivariate Cox Regression Analyses

The variables significantly related to poorer OS in univariate Cox regression analysis were gender (male); advanced age, T stage, N stage; smoking history; higher plasma pre-EBV-DNA (≥4000 copies/ml), pre-CRP (≥2 mg/L) and pre-LDH (≥180 U/L); lower pre-HGB (<120 g/L) and pre-ALB(<45 g/L); radiotherapy with induction chemotherapy (IC) (Table 3). Some phase III randomized trials proved that radiotherapy with concurrent chemotherapy (CC) is the standard therapy for advanced nasopharyngeal carcinoma, which remarkably ameliorates the survival of NPC patients (19, 20). In this study, radiotherapy with/without CC was an independent prognostic factor for DFS (Figure 1C). Thus, though radiotherapy with/without CC had a non-significant \( P \)-value of 0.076 for OS, we still regarded it as a necessary prognostic variable of survival in this study and put it into multivariate Cox regression analysis as well as the establishment of the nomogram. All factors above entered into multivariate Cox regression analysis. Finally, gender, age, T stage, N stage, plasma pre-EBV-DNA, pre-HGB, pre-CRP, pre-LDH, and radiotherapy with/without IC or CC were the significant prognostic factors. Detailed summaries of univariate and multivariate Cox analysis for OS, DMFS, and DFS were shown in Table 3 and Figure 1.

Establishing and Validating a Nomogram

For providing a clinically quantitative tool to predict OS, DMFS as well as DFS probability, a nomogram was created based on the important prognostic factors mentioned above. All factors were involved, including gender, age, 8th T stage, 8th N stage, plasma pre-EBV-DNA, pre-HGB, pre-CRP, pre-LDH, and radiotherapy with/without IC or CC. By aggregating the score of each variable and locating the total scores on the score scale, the nomogram was constructed to prognosticate 3- as well as 5-year OS, DMFS, and DFS in the primary cohort (Figures 2A–C).

The concordance index (C-index) for the nomogram to predict OS and DMFS over 0.7 in all cohorts indicated the model is satisfactory (Table 4). In the calibration plots, the x-axis was the prediction of OS, DMFS, or DFS computed by the nomogram, and the y-axis was the observed OS, DMFS, or DFS calculated by the Kaplan–Meier method. The solid line is the ideal reference line to represent the consistency between predicted survival and observed survival. Reassuringly, the calibration plots concerning the probability of three-year or five-year OS, DMFS, and DFS had remarkable correspondence between prediction and observation in all cohorts (Figure 3).

Comparison of the Eighth Edition of the UICC/AJCC TNM System and the Nomogram in Patients With NPC

The prognostic accuracy of the eighth edition of the TNM system and the nomogram concerning OS, DMFS, and DFS was compared in all cohorts. As a result, the nomogram had lower Akaike information criterion (AIC) value and higher C-index than the 8th TNM system when predicting OS, DMFS, and DFS in NPC patients (Table 4). It revealed that the nomogram had markedly higher predictive precision and discrimination than the TNM staging system. The ROC curves of 3- and 5-year OS, DMFS, and DFS also demonstrated the better predictive function of the nomogram (Figure 4). Further, the decision curve indicated that the nomogram had a higher net medical benefit than the 8th TMN stage across a broader range of threshold probabilities to prognosticate OS, DMFS, and DFS in both primary (Figures 5A, C, E) and validation (Figures 5B, D, F) cohorts.

Nomograms for Risk Stratification

Because the nomogram was better than the 8th edition TNM staging system to predict OS, DMFS, and DFS, stratification was
conducted based on the nomogram for OS, DMFS, and DFS. We set the cut-off values (the 33 and 66 percentiles) for the total scores calculated by the nomogram, by which the patients in the primary or validation cohorts were classified into low- [total score: <14 (OS); <11 (DMFS); <14 (DFS)], intermediate- [total score: 14–19 (OS); 11–15.5 (DMFS); 14–19 (DFS)] and high- [total score: > 9 (OS); >15.5 (DMFS); >19 (DFS)] risk groups. Table 5 listed the actual 3- and 5-year OS, DMFS and DFS rates in the low-, intermediate- and high-risk groups. In the Kaplan–Meier OS, DMFS, and DFS curves, the risk stratification indicated a significant distinction among different risk groups (all $P$-values < 0.001; Figure 6).

**DISCUSSION**

The 8th edition of the UICC/AJCC TNM staging system is the commonest predictor, by which NPC patients are classified based on the nomogram for OS, DMFS, and DFS. We set the cut-off values (the 33 and 66 percentiles) for the total scores calculated by the nomogram, by which the patients in the primary or validation cohorts were classified into low- [total score: <14 (OS); <11 (DMFS); <14 (DFS)], intermediate- [total score: 14–19 (OS); 11–15.5 (DMFS); 14–19 (DFS)] and high- [total score: > 9 (OS); >15.5 (DMFS); >19 (DFS)] risk groups. Table 5 listed the actual 3- and 5-year OS, DMFS and DFS rates in the low-, intermediate- and high-risk groups. In the Kaplan–Meier OS, DMFS, and DFS curves, the risk stratification indicated a significant distinction among different risk groups (all $P$-values < 0.001; Figure 6).
### TABLE 2 | The median follow-up for OS, DMFS, and DFS as well as the 3- and 5-year OS, DMFS, and DFS.

|                | OS       | DMFS     | DFS       | OS       | DMFS     | DFS       |
|----------------|----------|----------|-----------|----------|----------|-----------|
|                | primary cohort |          | validation cohort |          |          |          |
| median follow-up (month) | 76       | 76       | 74        | 53       | 53       | 52        |
| [range]        | [4–123]  | [3–123]  | [3–119]   | [2–65]   | [1–65]   | [1–65]    |
| 3-year survival (%) | 91.7     | 88.9     | 82.5      | 91.8     | 89.3     | 82.9      |
| 5-year survival (%) | 84.7     | 86.3     | 77.1      | 87.6     | 87.9     | 79.0      |

DFS, disease-free survival; DMFS, distant metastasis-free survival; OS, overall survival.

### TABLE 3 | Univariate Cox regression analysis of OS, DMFS, and DFS in the primary cohort.

| Variable | OS | | | DMFS | | | | DFS | | |
|----------|----|---|---|------|---|---|------|---|---|---|---|
|          | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Gender   |                |          |                |          |                |          |
| Male     | Reference      | <0.001   | Reference      | <0.001   | Reference      | <0.001   |
| Female   | 0.701 (0.606 to 0.812) |          | 0.593 (0.497 to 0.708) |          | 0.735 (0.650 to 0.830) |          |
| Age      |                |          |                |          |                |          |
| <40      | Reference      |          | Reference      |          | Reference      |          |
| 40–49    | 1.187 (1.011 to 1.394) | 0.036   | 1.090 (0.869 to 1.222) | 0.726   | 1.090 (0.957 to 1.241) | 0.194   |
| 50–59    | 1.534 (1.294 to 1.818) | <0.001  | 1.184 (0.983 to 1.427) | 0.075   | 1.290 (1.120 to 1.485) | <0.001  |
| ≥60      | 2.895 (2.427 to 3.451) | <0.001  | 1.477 (1.187 to 1.837) | <0.001  | 1.994 (1.709 to 2.326) | <0.001  |
| Smoking  | no             |          | Reference      |          | Reference      |          |
| yes      | 1.396 (1.240 to 1.573) | <0.001  | 1.386 (1.210 to 1.587) | <0.001  | 1.348 (1.218 to 1.491) | <0.001  |
| Drinking | no             |          | Reference      |          | Reference      |          |
| yes      | 1.168 (0.993 to 1.373) | 0.061   | 1.233 (1.029 to 1.478) | 0.023   | 1.192 (1.039 to 1.366) | 0.121   |
| Family history of tumor | no         |          | Reference      |          | Reference      |          |
| yes      | 0.918 (0.802 to 1.051) | 0.216   | 0.936 (0.803 to 1.092) | 0.402   | 0.913 (0.814 to 1.024) | 0.121   |
| 8th T stage | T1          |         | Reference      |          | Reference      |          |
| T2       | 1.887 (1.446 to 2.463) | <0.001  | 1.618 (1.222 to 2.141) | <0.001  | 1.835 (1.487 to 2.264) | <0.001  |
| T3       | 2.332 (1.853 to 2.934) | <0.001  | 1.834 (1.444 to 2.331) | <0.001  | 2.001 (1.668 to 2.400) | <0.001  |
| T4       | 4.076 (3.219 to 5.161) | <0.001  | 2.940 (2.291 to 3.773) | <0.001  | 3.299 (2.731 to 3.987) | <0.001  |
| 8th N stage | N0          |         | Reference      |          | Reference      |          |
| N1       | 1.907 (1.505 to 2.415) | <0.001  | 2.232 (1.655 to 3.010) | <0.001  | 1.791 (1.484 to 2.161) | <0.001  |
| N2       | 3.137 (2.453 to 4.013) | <0.001  | 4.089 (3.010 to 5.555) | <0.001  | 2.692 (2.207 to 3.284) | <0.001  |
| N3       | 4.859 (3.767 to 6.267) | <0.001  | 6.886 (5.040 to 9.408) | <0.001  | 3.922 (3.184 to 4.832) | <0.001  |
| pre-EBV-DNA | <4,000 copies/ml |         | Reference      |          | Reference      |          |
| ≥4,000 copies/ml | 2.266 (2.004 to 2.561) | <0.001  | 2.694 (2.332 to 3.112) | <0.001  | 2.118 (1.911 to 2.347) | <0.001  |
| pre-HGB   | <120 g/L      |         | Reference      |          | Reference      |          |
| ≥120 g/L  | 0.778 (0.623 to 0.971) | 0.027   | 0.798 (0.618 to 1.029) | 0.082   | 0.822 (0.678 to 0.997) | 0.046   |
| pre-ALB   | <45 g/L       |         | Reference      |          | Reference      |          |
| ≥45 g/L   | 0.686 (0.606 to 0.777) | <0.001  | 0.810 (0.705 to 0.930) | 0.003   | 0.809 (0.729 to 0.896) |          |
| pre-CRP   | <2 mg/L       |         | Reference      |          | Reference      |          |
| ≥2 mg/L   | 1.526 (1.356 to 1.718) | <0.001  | 1.461 (1.277 to 1.672) | <0.001  | 1.354 (1.226 to 1.497) | <0.001  |
| pre-LDH   | <180 U/L      |         | Reference      |          | Reference      |          |
| ≥180 U/L  | 1.501 (1.333 to 1.690) | <0.001  | 1.444 (1.261 to 1.654) | <0.001  | 1.381 (1.250 to 1.527) | <0.001  |
| IC        | No            |         | Reference      |          | Reference      |          |
| Yes       | 1.423 (1.263 to 1.603) | <0.001  | 1.509 (1.316 to 1.730) | <0.001  | 1.408 (1.273 to 1.557) | <0.001  |
| CC        | No            |         | Reference      |          | Reference      |          |
| Yes       | 1.145 (0.986 to 1.329) | 0.076   | 1.260 (1.057 to 1.503) | 0.01    | 1.156 (1.018 to 1.311) | 0.025   |

CI, confidence interval; HR, hazard ratio.

Cox proportional hazard model was used to conduct Cox regression analysis.
on T (tumor size), N (lymph node involvement), as well as M (distant metastasis). Nevertheless, the survival of NPC patients differs significantly in the same T, N, M stage (21, 22). This phenomenon may be partly due to the TNM system, which is unable to reflect the NPC patients' prognosis completely. Thus, we need a more reliable prognostic tool to precisely predict which patients may obtain clinical benefit from more intensive therapy and avoid overtreatment.

In this study, we established and validated a nomogram for predicting OS, DMFS, and DFS in NPC patients based on serum biomarkers and clinical characteristics. The nomogram remarkably outperformed the 8th TNM system to predict 3- and 5-year OS, DMFS, and DFS, which would assist clinicians in distinguishing high-risk NPC patients as well as selecting suitable therapies.

Several serum markers serve as potential predictors of prognosis in patients with NPC. For instance, previous studies demonstrated that increased EBV-DNA level is related to local recurrence as well as distant metastasis. It is closely associated with the extent of tumor, serving as a tumor biomarker to predict survival of NPC patients (23–25). HGB is a significant marker of patients' nutritional status. Its level reveals the state of hypoxia in tumor tissues. Some studies indicated that decreased HGB is significantly related to poorer prognosis in patients with NPC (26, 27). ALB is also an important indicator reflecting the patients' nutritional status and has been used for prognostic assessment of patients with NPC (28). CRP, an acute-phase protein, increases quickly related to inflammation or infection (29). High level of serum CRP in NPC patients is associated with poor prognosis (30). LDH is also a prognostic marker in NPC patients, high level of which represents worse 5-year OS, DMFS, and DFS (31).

Based on these studies, the levels of pre-EBV-DNA, pre-HGB, pre-ALB, pre-CRP, and pre-LDH have been evaluated in this study, combined with gender, age, T stage, N stage, smoking, drinking history, family history of tumor, and radiotherapy with/without IC or CC. We recognized the significant prognostic factors for OS, DMFS, and DFS through univariate and multivariate Cox analyses, which included gender, age, T stage, N stage, pre-EBV-DNA, pre-HGB, pre-CRP, pre-LDH, and radiotherapy with/without IC or CC. Based on these predictive factors, the nomogram model was thus established.

**FIGURE 1** | Multivariate Cox regression analysis of OS (A), DMFS (B), and DFS (C) in the primary cohort. ALB, albumin; CC, concurrent chemotherapy; CI, confidence interval; CRP, C-reactive protein; DFS, disease-free survival; DMFS, distant metastasis-free survival; EBV-DNA, Epstein–Barr virus DNA; HR, hazard ratio; HGB, hemoglobin; IC, induction chemotherapy; LDH, lactate dehydrogenase; OS, overall survival; pre-, pretreatment (pre-). Cox proportional hazard model was used to conduct Cox regression analysis.
FIGURE 2 | Establishing a nomogram. Nomogram was based on gender, age, T stage, N stage, plasma pre-EBV-DNA, pre-HGB, pre-CRP, pre-LDH, and radiotherapy with/without induction or concurrent chemotherapy for 3-, 5-year OS (A), DMFS (B), and DFS (C) in NPC patients in the primary cohort.

TABLE 4 | Comparison of the eighth edition of the UICC/AJCC TNM system and the nomogram in patients with NPC.

|                | the 8th TNM system | the nomogram | P-value |
|----------------|--------------------|--------------|---------|
|                | AIC | C-index (95% CI) | AIC | C-index (95% CI) |         |
| primary cohort | OS  | 18,447.63        | 0.669 (0.653–0.685) | 18,245.68 | 0.710 (0.696–0.724) | <0.01   |
|                | DMFS| 14,253.72        | 0.673 (0.655–0.691) | 14,150.26 | 0.705 (0.689–0.720) | <0.01   |
|                | DFS | 25,825.26        | 0.643 (0.629–0.657) | 25,672.22 | 0.672 (0.658–0.686) | <0.01   |
| validation     | OS  | 6,072.35         | 0.659 (0.633–0.684) | 5,977.36  | 0.715 (0.691–0.739) | <0.01   |
|                | DMFS| 6,427.71         | 0.656 (0.631–0.681) | 6,364.74  | 0.701 (0.677–0.725) | <0.01   |
|                | DFS | 11,078.11        | 0.642 (0.622–0.662) | 11,000.83 | 0.677 (0.657–0.697) | <0.01   |

AIC, Akaike information criterion.
FIGURE 3 | Calibration plots for 3- and 5-year OS, DMFS, and DFS in the primary (A, C, E, G, I, K) and validation cohorts (B, D, F, H, J, L). Nomogram-predicted 3- or 5-year OS (A–D), DMFS (E–H), and DFS (I–L) were plotted on the x-axis; Kaplan–Meier calculated outcomes were plotted on the y-axis. The dashed 45-degree lines serve as the best situation indicating the predicted probabilities are equal to the actual probabilities.
The nomogram showed a significant improvement in OS, DMFS, and DFS prediction of NPC patients when compared with the TNM stage system. The model was also tested in the independent validation cohort, verifying its reliability and reproducibility. Also, according to the nomogram, we divided patients into high, intermediate, and low-risk groups, in which the high-risk group had a markedly poor OS, DMFS, and DFS.

There are four main advantages of the study. First, we had a relatively large number of patients (9,340 patients) that made the conclusion more convictive. Second, after integrating clinical features, serum markers, and the selection of therapy items into the nomogram, our nomogram can predict the survival of NPC patients more comprehensively than the TNM staging system. Third, we can get all variables included in the nomogram easily...
**FIGURE 5** | Decision curve analysis for OS, DMFS, and DFS prediction. The decision curves of the primary cohort (5-year OS, DMFS, and DFS) (A, C, E) and the validation cohort (3-year OS, DMFS, and DFS) (B, D, F).

**TABLE 5** | Nomograms for risk stratification.

|          | primary cohort | validation cohort |
|----------|----------------|-------------------|
|          | low-risk | intermediate-risk | high-risk | low-risk | intermediate-risk | high-risk |
| 3-year   | OS       | 98.2%  | 93.4%  | 83.9%  | 97.6%  | 92.7%  | 85.0%  |
|          | DMFS     | 96.9%  | 91.1%  | 79.0%  | 96.0%  | 90.3%  | 81.2%  |
|          | DFS      | 92.8%  | 84.5%  | 69.9%  | 92.0%  | 84.1%  | 71.4%  |
| 5-year   | OS       | 95.6%  | 87.0%  | 72.0%  | 96.2%  | 95.4%  | 90.7%  |
|          | DMFS     | 95.3%  | 88.4%  | 75.9%  | 89.6%  | 88.9%  | 78.8%  |
|          | DFS      | 89.3%  | 78.6%  | 63.2%  | 77.0%  | 78.9%  | 66.2%  |
in most medical institutions, so the nomogram has wide generalizability. Last but not least, the nomogram serves as a visualized prediction tool, which may help doctors to evaluate patients with their expected survival rapidly via simple calculation in clinical practice. The classification of patients with different severity of the disease is beneficial to determine appropriate therapies.

To be honest, our study also has some limitations. At first, the study served as a retrospective study, which would have an inevitable selection bias. But this kind of retrospective studies is worth performing because it is significant to the design of some prospective studies. Secondly, all the cohorts involved patients at a single hospital, which may limit the applicability of our findings for patients from other geographical regions and institutions.

FIGURE 6 | Kaplan–Meier curves of OS (A, B), DMFS (C, D), and DFS (E, F) for low-, intermediate- and high-risk groups. The stratifications of risk groups were based on the 33 and 66 percentiles of total scores in the primary (A, C, E) and validation cohorts (B, D, F).
However, the large primary cohort (more than 5,500 patients) and the independent validation cohort could largely enhance the convincingness of results.

In summary, we established and validated a nomogram to predict OS, DMFS, and DFS in NPC patients, which involved gender, age, T stage, N stage, pre-EBV-DNA, pre-HGB, pre-CRP, pre-LDH, and radiotherapy with/without IC or CC. The nomogram showed outstanding discriminative ability as well as satisfactory consistency to classify patients with NPC into low-, intermediate- and high-risk groups, which can provide helpful clues for doctors to identify the high-risk NPC patients and select suitable treatments.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Hospital Ethics Committee at Sun Yat-sen University Cancer Center. Written informed consent from the participants’ legal guardian/next of kin was not required to participate in this study in accordance with the national legislation and the institutional requirements.

REFERENCES

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. *Lancet* (2005) 365:2041–54. doi: 10.1016/S0140-6736(05)66698-6
2. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. *Cancer Cell* (2004) 5:423–8. doi: 10.1016/j.ccl.2004.04.001
3. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. *Oral Oncol* (2014) 50:330–8. doi: 10.1016/j.oraloncology.2014.02.006
4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* (2018) 68:394–424. doi: 10.3322/caac.21492
5. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. *J Clin Oncol* (2002) 20:2038–44. doi: 10.1200/JCO.2002.08.149
6. Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. *Lancet* (2016) 388:1883–92. doi: 10.1016/S0140-6736(16)31388-5
7. OuYang PY, Su Z, Ma HA, Yao OP, Liu ZM, Xie FY. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. *Br J Cancer* (2013) 109:2987–97. doi: 10.1038/bjc.2013.659
8. OuYang PY, Xiao Y, You KY, Zhang LN, Lan XW, Zhang XM, et al. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. *Oral Oncol* (2017) 72:65–72. doi: 10.1016/j.oraloncology.2017.07.011
9. Yang XL, Wang Y, Liang SB, He SS, Chen DM, Chen HY, et al. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers. *BMC Cancer* (2018) 18:606. doi: 10.1186/s12885-018-4419-1
10. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. *Philos Trans R Soc Lond B Biol Sci* (2017) 372:20160270. doi: 10.1098/rstb.2016.0270
11. Chang H, Gao J, Xu BQ, Guo SP, Lu RB, Li G, et al. Haemoglobin, neutrophil to lymphocyte ratio and platelet count improve prognosis prediction of the TNM staging system in nasopharyngeal carcinoma: development and validation in 3,237 patients from a single institution. *Clin Oncol (R Coll Radiol)* (2013) 25:639–46. doi: 10.1016/j.clonc.2013.07.004
12. Li G, Gao J, Liu ZG, Tao YL, Xu BQ, Tu ZW, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution. *Head Neck* (2014) 36:660–6. doi: 10.1002/hed.23357
13. Tang LQ, Li CF, Chen QY, Zhang L, Lai XP, He Y, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. *Int J Radiat Oncol Biol Phys* (2015) 91:325–36. doi: 10.1016/j.ijrobp.2014.10.005
14. Li G, Gao J, Tao YL, Xu BQ, Tu ZW, Liu ZG, et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. *Chin J Cancer* (2012) 31:197–206. doi: 10.5732/cjc.011.10283
15. Wang Y, Li J, Xiao Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. *J Clin Oncol* (2013) 31:1188–95. doi: 10.1200/JCO.2012.41.5984
16. Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, et al. Nomograms to Predict Recurrence-Free and Overall Survival After Curative Resection of Adenocarcinoma. *JAMA Surg* (2016) 151:365–73. doi: 10.1001/jamasurg.2015.4516
17. Sun XS, Liang YJ, Liu SL, Li XY, Chen QY, Guo SS, et al. Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma. *Oral Oncol* (2019) 94:73–9. doi: 10.1016/j.oraloncology.2019.05.015

AUTHOR CONTRIBUTIONS

Study conception and design (L-LT, LC, and JM). Data acquisition (Y-PM, RG, C-LH, and X-LF). Data analysis and interpretation (Q-JL, Y-PM, RG, and LC). Quality control of data and algorithms (Q-JL, Y-PM, and RG). Manuscript writing (Q-JL, Y-PM, RG, and L-LT). Manuscript reviewing and approving (L-LT, LC, and JM). All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by grants from the National Natural Science Foundation of China (81930072), Key-Area Research and Development Program of Guangdong Province (2019B020230002), Natural Science Foundation of Guangdong Province (2017A030312003), Health & Medical Collaborative Innovation Project of Guangzhou City, China (201803040003), Innovation Team Development Plan of the Ministry of Education (No. IRT_17R110), Overseas Expertise Introduction Project for Discipline Innovation (111 Project, B14035).
18. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *Clin Oncol* (2008) 26:1364–70. doi: 10.1200/JCO.2007.12.9791

19. Chan AT, Leung SF, Ngan RK, Teo PM, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* (2005) 97:536–9. doi: 10.1093/jnci/dji084

20. Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. *J Natl Cancer Inst* (2011) 103:1761–70. doi: 10.1093/jnci/djr432

21. Xu J, Wan XB, Huang XF, Chan KC, Hong MH, Wang LH, et al. Serologic anti-enzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. *Clin Oncol* (2010) 28:5202–9. doi: 10.1200/JCO.2009.25.6552

22. Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, et al. Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. *Clin Oncol* (2011) 29:4516–25. doi: 10.1200/JCO.2010.33.7741

23. Xu M, Yao Y, Chen H, Zhang S, Cao SM, Zhang Z, et al. Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. *Nat Genet* (2019) 51:1131–6. doi: 10.1038/s41588-019-0436-5

24. Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* (2007) 67:130–7. doi: 10.1016/j.ijrobp.2006.07.012

25. Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. *Cancer* (2013) 119:963–70. doi: 10.1002/cncr.27853

26. Gao J, Tao YL, Li G, Yi W, Xia YF. Involvement of difference in decrease of hemoglobin level in poor prognosis of Stage I and II nasopharyngeal carcinoma: implication in outcome of radiotherapy. *Int J Radiat Oncol Biol Phys* (2012) 82:1471–8. doi: 10.1016/j.ijrobp.2011.05.009

27. Zhang LN, Tang J, Lan XW, OuYang PY, Xie FY. Pretreatment anemia and survival in nasopharyngeal carcinoma. *Tumour Biol* (2016) 37:2225–31. doi: 10.1007/s13277-015-4042-6

28. Yang H, Wang K, Liang Z, Guo S, Zhang P, Xu Y, et al. Prognostic role of pretreatment serum albumin in patients with nasopharyngeal carcinoma: A meta-analysis and systematic review. *Clin Otalaryngol* (2020) 45:167–76. doi: 10.1111/coa.13454

29. Peisajovich A, Marnell L, Mold C, Du Clos TW. C-reactive protein at the interface between innate immunity and inflammation. *Expert Rev Clin Immunol* (2008) 4:379–90. doi: 10.1586/1744666X.4.3.379

30. Chen R, Zhou Y, Yuan Y, Zhang Q, He S, Chen Y, et al. Effect of CRP and Kinetics of CRP in Prognosis of Nasopharyngeal Carcinoma. *Front Oncol* (2019) 9:89. doi: 10.3389/fonc.2019.00089

31. Wan XB, Wei L, Li H, Dong M, Lin Q, Ma XK, et al. High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. *Eur J Cancer* (2013) 49:2356–64. doi: 10.1016/j.ejca.2013.03.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Li, Mao, Huang, Fang, Ma, Tang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.